Q1 2026 AbbVie Inc Earnings Call Transcript
Key Points
- AbbVie Inc (ABBV) reported first-quarter results that exceeded expectations, with adjusted earnings per share of $2.65, surpassing guidance by $0.07.
- Total net revenues reached $15 billion, reflecting a robust sales growth of 12.4%, driven by strong performance in immunology and neuroscience.
- The company raised its full-year adjusted earnings per share guidance by $0.12, now expecting between $14.08 and $14.28.
- Significant progress in R&D, including US regulatory submissions for Rinvoq in Alopecia Areata and promising interim data from the Crohn's platform study.
- AbbVie Inc (ABBV) continues to expand its oncology pipeline, closing the RemeGen agreement for a novel PD-1/VEGF bispecific antibody.
- Humira global sales declined by 40.3% on an operational basis due to biosimilar competition, aligning with expectations.
- Juvederm global sales decreased by 2.9%, reflecting continued headwinds in key dermal filler markets.
- The aesthetics segment faced economic headwinds, impacting market conditions globally, despite long-term prospects remaining attractive.
- The FDA issued a complete response letter for TrenibotE related to manufacturing questions, delaying its approval in the US.
- In oncology, total revenues decreased by 3% on an operational basis, with Imbruvica sales down 24.7% due to IRA pricing and competitive pressures.
Good morning and thank you for standing by. Welcome to the AbbVie first quarter 2026 earnings conference call. (Operator Instructions) Today's call is also being recorded. If you have any objections, you may disconnect at this time.
I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.
Good morning, and thanks for joining us. Also on the call with me today are Rob Michael, Chairman and Chief Executive Officer; Jeff Stewart, Executive Vice President, Chief Commercial Officer; Roopal Thakkar, Executive Vice President, Research and Development and Chief Financial Officer; and Scott Reents, Executive Vice President and Chief Financial Officer.
Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause our actual results to differ materially from those indicated in our forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
